[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561645":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":27,"interventions":64,"overallOfficials":17,"centralContacts":74,"locations":80,"responsibleParty":107,"collaborators":109,"id":115,"slug":116,"hasResults":117,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":123,"sex":124,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":17,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":82,"whyStopped":17,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},{"fullName":5,"class":6},"People's Hospital of Quzhou","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Comprehensive evaluation of NMN in reducing biological age","Change in biological age from baseline to 12 months, quantified using predefined multi-layer aging clock(s).\n\nBiological age will be assessed using the following measures:\n\n1. Transcriptomic age (years)\n2. DNA methylation age (years)\n3. Proteomic age (years)\n4. Metabolomic age (years)\n5. Phenotypic age (years)\n\nThe primary endpoint will be defined as:\n\nChange from baseline to 12 months in a prespecified composite biological age score, derived from the above aging clocks using a predefined integration method (e.g., standardized z-score aggregation or principal component-based integration).\n\nA reduction in biological age is defined as a decrease in the composite biological age score.","Baseline, 6 months and 12 months",[14],{"measure":15,"description":16,"timeFrame":12},"Composite through clinical physical examination data, behavioral indicators and multilevel omics data, to discover new sensitive biomarkers for evaluating aging.","NMN intervention-associated changes will be evaluated across predefined domains:\n\n1. Clinical examination parameters, such as:\n\n   1. Bone mineral density (g\u002Fcm²)\n   2. Pulmonary function, including FEV1 (L), FVC (L), and FEV1\u002FFVC (%) Each parameter will be analyzed individually.\n2. Functional performance measures, such as:\n\n   1. Grip strength (kg)\n   2. Purdue Pegboard Test completion time (s) Improvement is defined as an increase in grip strength and a decrease in completion time.\n3. Inflammatory and clinical biomarkers, such as:\n\n   Circulating inflammatory markers (e.g., IL-6 \\[pg\u002FmL\\], CRP \\[mg\u002FL\\]) Improvement is defined as a reduction in these markers.\n4. Multi-omics-derived aging biomarkers, such as:\n\nGene expression, proteomic, and metabolomic profiles related to metabolism, immunity, and aging. These measures will be summarized using:\n\nPredefined composite aging scoresm, biological ages, or principal component-based or pathway-level summaries, depending on the analysis framework.",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"RANDOMIZED","PARALLEL","BASIC_SCIENCE",{"masking":23,"maskingDescription":17,"whoMasked":24},"DOUBLE",[25,26],"PARTICIPANT","INVESTIGATOR",[28,34,40,44,48,52,56,60],{"label":29,"type":30,"description":31,"interventionNames":32},"NMN treated (middle-aged female)","EXPERIMENTAL","NMN Arm participants (middle-aged female) took one capsule (containing 350mg NMN) with breakfast daily for one year.",[33],"Dietary Supplement: NMN",{"label":35,"type":36,"description":37,"interventionNames":38},"Placebo (middle-aged male)","PLACEBO_COMPARATOR","Placebo arm participants (middle-aged male) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.",[39],"Dietary Supplement: placebo",{"label":41,"type":30,"description":42,"interventionNames":43},"NMN treated (middle-aged male)","NMN Arm participants (middle-aged male) took one capsule (containing 350mg NMN) with breakfast daily for one year.",[33],{"label":45,"type":30,"description":46,"interventionNames":47},"NMN treated (old female)","NMN Arm participants (old female) took one capsule (containing 350mg NMN) with breakfast daily for one year.",[33],{"label":49,"type":30,"description":50,"interventionNames":51},"NMN treated (old male)","NMN Arm participants (old male) took one capsule (containing 350mg NMN) with breakfast daily for one year.",[33],{"label":53,"type":36,"description":54,"interventionNames":55},"Placebo (middle-aged female)","Placebo arm participants (middle-aged female) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.",[39],{"label":57,"type":36,"description":58,"interventionNames":59},"Placebo (old male)","Placebo arm participants (old male) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.",[39],{"label":61,"type":36,"description":62,"interventionNames":63},"Placebo (old female)","Placebo arm participants (old female) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.",[39],[65,70],{"type":66,"name":67,"description":68,"armGroupLabels":69,"otherNames":17},"DIETARY_SUPPLEMENT","NMN","NMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.",[29,41,45,49],{"type":66,"name":71,"description":72,"armGroupLabels":73,"otherNames":17},"placebo","Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.",[53,35,61,57],[75],{"name":76,"role":77,"phone":78,"phoneExt":17,"email":79},"Feng Zhang","CONTACT","+86-15657053100","felix.f.zhang@outlook.com",[81],{"facility":5,"status":82,"city":83,"state":84,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":93,"contacts":94},"RECRUITING","Quzhou","Zhejiang","324000","China","CN",{"type":89,"coordinates":90},"Point",[91,92],118.86861,28.95944,{"lat":92,"lon":91},[95,99,102,105],{"name":96,"role":77,"phone":97,"phoneExt":17,"email":98},"Beier Jiang","+86-18367091390","beierjiang@wmu.edu.cn",{"name":100,"role":101,"phone":17,"phoneExt":17,"email":17},"Feng Zhang, Professor","PRINCIPAL_INVESTIGATOR",{"name":103,"role":104,"phone":17,"phoneExt":17,"email":17},"Guanghui Liu, Professor","SUB_INVESTIGATOR",{"name":106,"role":104,"phone":17,"phoneExt":17,"email":17},"Weiqi Zhang, Professor",{"type":101,"investigatorFullName":76,"investigatorTitle":108,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"researcher",[110,113],{"name":111,"class":112},"Beijing Institute of Genomics, Chinese Academy of Sciences","OTHER_GOV",{"name":114,"class":112},"Institute of Zoology, Chinese Academy of Sciences","100561645","intervention-of-nicotinamide-mononucleotide-in-middle-aged-and-elderly-people-100561645",false,"NCT06592859","Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People","Quzhou Population Cohort Research Project (Aging Related Research: Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People)","NMNAGING","Inclusion criteria：\n\n1. Local residents of Quzhou or living in Quzhou for over ten years.\n2. age 40-50 and 60-70 years old, no major bad habits.\n3. Gender unlimited.\n4. in good health and has not undergone major surgery within half a year.\n5. Be able to communicate well with researchers and cooperate with the work during the study.\n6. Written informed consent can be signed voluntarily.\n\nExclusion criteria：\n\n1. Alcoholism, heavy smoking (more than 5 packs\u002Fday, 20 cigarettes per pack), drug abuse or substance abuse.\n2. Participants are conducting other clinical trials or using any research drugs or equipment for treatment within 30 days before enrollment (including but not limited to aspirin, metformin, resveratrol, vitamin C, etc.).\n3. Obesity (bmi more than 30).\n4. Pregnant\u002Flactating women.\n5. Disease history:\n\n   A) under 60 years old:\n   1. any cancer (erythrocytosis, except basal cell or squamous cell skin cancer).\n   2. coronary artery disease\u002Fmyocardial infarction\u002Fclinically significant congestive heart failure.\n   3. stroke\u002Ftransient ischemic attack.\n   4. deep vein thrombosis\u002Fpulmonary embolism.\n   5. serum creatinine \\> 1.5 mg\u002Fdl (male).\n   6. poor control of hypertension (although treated, there is still significant hypertension (systolic blood pressure \\> 160 mmHg, or diastolic blood pressure \\>100 mmHg)).\n   7. history of active liver disease or metabolic acidosis.\n   8. chronic kidney disease\u002Fhemodialysis treatment, history of severe kidney damage and\u002For EGFR ≤ 45ml\u002Fmin\u002F1.73m2.\n   9. severe autoimmunity\u002Finflammation, such as rheumatoid arthritis, lupus, Crohn\\'s disease, etc.\n   10. nervous system diseases such as dementia, such as Alzheimer\u002FParkinson\\'s disease.\n   11. diabetes mellitus (hemoglobin \\> 6.5% or fasting blood glucose \\> 126 mg\u002FdL or taking diabetes drugs or insulin treatment).\n   12. recent (within 3 months) cardiovascular events (myocardial infarction, coronary intervention, coronary artery bypass grafting).\n   13. infectious diseases such as HIV, hepatitis, tuberculosis, etc.\n   14. hand or lower limb disability affects normal function and life.\n\n   B) older than 60 years:\n   1. any cancer (erythrocytosis, except basal cell or squamous cell skin cancer).\n   2. history of active liver disease or metabolic acidosis.\n   3. chronic kidney disease\u002Fhemodialysis treatment, history of severe kidney damage and\u002For EGFR ≤ 45ml\u002Fmin\u002F1.73m2.\n   4. severe autoimmunity\u002Finflammation, such as lupus, Crohn\\'s disease, etc.\n   5. nervous system diseases such as dementia, such as Alzheimer\u002FParkinson\\'s disease.\n   6. recent (within 3 months) cardiovascular events (myocardial infarction, coronary intervention, coronary artery bypass grafting).\n   7. infectious diseases such as HIV, hepatitis, tuberculosis, etc.\n   8. hand or lower limb disability affects normal function and life.\n6. Currently taking the following drugs regularly:\n\n   A) chemotherapy drugs (such as tamoxifen, adriamycin, mitoxantrone, bleomycin). B) antiplatelet drugs (e.g., clopidogrel\u002FPlavix, dipyridamole\u002Fanglionide, ticlopidine\u002Fticlopidine, except aspirin).\n\n   C) cholinesterase inhibitors for Alzheimer\\'s disease (donepezil\u002Falicept).\n7. The researchers believe that the physical factors of the participants may have an adverse impact on the research process or results.",true,"ALL","39 Years","70 Years",{"count":128,"type":129},240,"ESTIMATED","INTERVENTIONAL",[132],"NA","This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.",[135,67],"Aging",[135,67],"2026-05-04",{"date":139,"type":140},"2026-05-08","ACTUAL",{"date":142,"type":140},"2023-08-23",{"date":144,"type":129},"2026-12-31",{"name":5,"class":6},1]